Research programme: T cell engagers - IGM Biosciences
Alternative Names: IgM T-cell engagersLatest Information Update: 12 Jul 2024
At a glance
- Originator IGM Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours